{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T16:24:56Z","timestamp":1773246296926,"version":"3.50.1"},"reference-count":13,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,7]]},"DOI":"10.1097\/wnf.0b013e31819a689f","type":"journal-article","created":{"date-parts":[[2009,7,28]],"date-time":"2009-07-28T07:54:11Z","timestamp":1248767651000},"page":"193-198","source":"Crossref","is-referenced-by-count":10,"title":["High Doses of Rotigotine Transdermal Patch"],"prefix":"10.1097","volume":"32","author":[{"given":"Ivan","family":"Rektor","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomislav","family":"Babic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernard","family":"Boothmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiri","family":"Polivka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Babak","family":"Boroojerdi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olaf","family":"Randerath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-4-20210203","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/mds.1090","article-title":"Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature.","volume":"16","author":"Ahlskog","year":"2001","journal-title":"Mov Disord"},{"issue":"Suppl 1","key":"R2-4-20210203","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00003495-199855001-00001","article-title":"The significance of continuous dopaminergic stimulation in the treatment of Parkinson's disease.","volume":"55","author":"Chase","year":"1998","journal-title":"Drugs"},{"issue":"Suppl 10","key":"R3-4-20210203","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1016\/S1471-1931(00)00030-6","article-title":"Continuous dopamine-receptor stimulation in early Parkinson's disease.","volume":"23","author":"Olanow","year":"2000","journal-title":"Trends Neurosci"},{"key":"R5-4-20210203","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1111\/j.1468-1331.2006.01547.x","article-title":"Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society-European Section. Part I: early (uncomplicated) Parkinson's disease.","volume":"13","author":"Horstink","year":"2006","journal-title":"Eur J Neurol"},{"issue":"Suppl 3","key":"R6-4-20210203","doi-asserted-by":"crossref","first-page":"S585","DOI":"10.1002\/mds.22022","article-title":"Preventing and controlling dyskinesia in Parkinson's disease-a view of current knowledge and future opportunities.","volume":"23","author":"Jenner","year":"2008","journal-title":"Mov Disord"},{"key":"R8-4-20210203","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1097\/01.WNF.0000228179.83335.65","article-title":"Rotigotine transdermal patch enables rapid titration to effective doses in advanced-stage idiopathic Parkinson disease: subanalysis of a parallel group, open-label, dose-escalation study.","volume":"29","author":"Babic","year":"2006","journal-title":"Clin Neuropharmacol"},{"key":"R10-4-20210203","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/archneur.60.12.1721","article-title":"A controlled trial of rotigotine monotherapy in early Parkinson's disease.","volume":"60","year":"2003","journal-title":"Arch Neurol"},{"key":"R11-4-20210203","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1097\/01.wnf.0000162228.00154.ba","article-title":"Safety, tolerability, and efficacy of continuous transdermal dopaminergic stimulation with rotigotine patch in early-stage idiopathic Parkinson disease.","volume":"28","author":"Guldenpfennig","year":"2005","journal-title":"Clin Neuropharmacol"},{"key":"R12-4-20210203","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1002\/mds.21741","article-title":"Rotigotine transdermal patch in early Parkinson's disease: a randomized, double-blind, controlled study versus placebo and ropinirole.","volume":"22","author":"Giladi","year":"2007","journal-title":"Mov Disord"},{"key":"R13-4-20210203","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1212\/01.wnl.0000252355.79284.22","article-title":"Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease.","volume":"68","author":"Watts","year":"2007","journal-title":"Neurology"},{"key":"R15-4-20210203","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/00002826-200105000-00008","article-title":"Continuous transdermal dopaminergic stimulation in advanced Parkinson's disease.","volume":"24","author":"Metman","year":"2001","journal-title":"Clin Neuropharmacol"},{"key":"R16-4-20210203","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1212\/01.wnl.0000259516.61938.bb","article-title":"Advanced Parkinson disease treated with rotigotine transdermal system. PREFER Study.","volume":"68","author":"LeWitt","year":"2007","journal-title":"Neurology"},{"key":"R17-4-20210203","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S1474-4422(07)70108-4","article-title":"Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial.","volume":"6","author":"Poewe","year":"2007","journal-title":"Lancet Neurol"}],"container-title":["Clinical Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/WNF.0b013e31819a689f","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T07:13:50Z","timestamp":1620976430000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002826-200907000-00004"}},"subtitle":["Results of an Open-Label, Dose-Escalation Trial in Patients With Advanced-Stage, Idiopathic Parkinson Disease"],"short-title":[],"issued":{"date-parts":[[2009,7]]},"references-count":13,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/wnf.0b013e31819a689f","relation":{},"ISSN":["0362-5664"],"issn-type":[{"value":"0362-5664","type":"print"}],"subject":[],"published":{"date-parts":[[2009,7]]}}}